Comparative Pharmacology
Head-to-head clinical analysis: HAILEY FE 1 5 30 versus PHILITH.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HAILEY FE 1 5 30 versus PHILITH.
HAILEY FE 1.5/30 vs PHILITH
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination estrogen-progestin contraceptive that suppresses gonadotropin release (FSH and LH) from the pituitary, inhibiting ovulation. Additionally, increases viscosity of cervical mucus and alters endometrial receptivity.
PHILITH is a combined oral contraceptive containing ethinyl estradiol and drospirenone. Ethinyl estradiol suppresses gonadotropin release, while drospirenone is a progestin with antiandrogenic and antimineralocorticoid activity, inhibiting ovulation and altering cervical mucus.
One tablet orally once daily for 21 consecutive days, followed by 7 days of placebo tablets.
1 mg orally once daily
None Documented
None Documented
Ethinyl estradiol: terminal half-life ~17-24 hours; norethindrone: terminal half-life ~5-14 hours (mean 11 hours). The clinical significance is that steady-state is reached within 5-7 days.
Terminal half-life 12 hours; clinically relevant for twice-daily dosing with steady state reached after 2-3 days.
Ethinyl estradiol is primarily excreted renally (40-45%) and via bile/feces (45-55%). Norethindrone is excreted 50-60% renally and 30-40% fecally.
Renal: 90% unchanged; biliary/fecal: 10% as metabolites.
Category C
Category C
Oral Contraceptive
Oral Contraceptive